Literature DB >> 2146403

Surgical treatment of renal artery stenosis after failed percutaneous transluminal angioplasty.

A G Martinez1, A C Novick, J M Hayes.   

Abstract

From 1980 to 1989, 53 patients with renovascular hypertension underwent surgical treatment after initial unsuccessful management with percutaneous transluminal angioplasty. Renal artery stenosis was due to fibrous dysplasia in 17 patients and atherosclerosis in 36. The reasons for failure of percutaneous transluminal angioplasty were inability to dilate the stenotic lesion (32 patients), acute renal arterial occlusion (2) or dissection (8) from attempted percutaneous transluminal angioplasty, and the development of recurrent renal artery stenosis after initially successful percutaneous transluminal angioplasty (11). Three patients underwent nephrectomy due to the finding of a nonviable kidney at operation. Successful surgical revascularization was achieved in 50 patients. There was no significant fibrosis or inflammation around the previously dilated renal artery. Percutaneous transluminal angioplasty necessitated performance of a more complicated revascularization operation in only 1 patient. If the kidney is viable at operation in patients treated by percutaneous transluminal angioplasty renovascular reconstruction is not more technically difficult than when done primarily and the same excellent results can be achieved.

Entities:  

Mesh:

Year:  1990        PMID: 2146403     DOI: 10.1016/s0022-5347(17)39666-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

1.  Renal artery revascularization after unsuccessful percutaneous therapy: a single centre experience.

Authors:  Kai M Balzer; S Neuschäfer; T A Sagban; D Grotemeyer; T Pfeiffer; L C Rump; W Sandmann
Journal:  Langenbecks Arch Surg       Date:  2011-10-18       Impact factor: 3.445

2.  Renal artery reconstruction in transplant kidney. Case report.

Authors:  S Sert; A Dalgiç; S Sindel; U Boztepe; E Ilgit; E Hasanoğlu
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.